InvestorsHub Logo
Followers 38
Posts 6888
Boards Moderated 1
Alias Born 09/06/2014

Re: None

Sunday, 01/25/2015 9:06:01 AM

Sunday, January 25, 2015 9:06:01 AM

Post# of 30046
GCDx crowdsourcing campaign is over.

https://www.indiegogo.com/projects/save-a-life-with-the-lung-cancer-test

$505 raised, and nobody selected the test as a "perk" except Roberton.

If GCDx is just a "smokescreen and diversion" for the Radient takeover as some suggest, this crowdsourcing campaign was internet fraud in my opinion. GCDx is presenting itself as a real company actively trying to sell a lung cancer test, and they took people's money for that purpose. True, they didn't take MANY people's money, but that is not from lack of trying.

GCDx is a legitimate company, IMO, and they are trying to sell a Lung Cancer Test. I don't see even the most REMOTE reason for Gartner to be involved with a takeover of merger with Radient Pharmaceuticals. What Gartner needs is funding and Radient Pharmaceuticals is insolvent.

So we have now proved that Provista is not using DR-70 in their tests, we have proved that Gartner's new company GCDx is legitimate and operating independently, and we have proved that Charter is more interested in his Saliva Test than in Radient Pharmaceuticals. When we remove Provista, GCDx, and Charter from the list of takeover/merger candidates, who is left?

I vote for Astellas. Or Fortis. Flip a coin?

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.